FSD Pharma Inc (HUGE)

[Mbern37]

Commenting on the purchase, FSD Pharma’s CEO Raza Bokhari told Benzinga:

“The Prismic Pharmaceuticals acquisition demonstrates the strategic depth in our vision for FSD Pharma and signals a paradigm shift in the overall outlook of the company. FSD Pharma can now embark upon R&D of drugs through the various stages of the FDA approval process, with the goal of eventually making synthetic cannabinoid & opioid sparing prescription medications targeting the human endocannibinoid system and make them available for commercial use.”